November 2025

Breakthrough Glaucoma Monitoring Device Secures CIHR Commercialization Funding In a significant milestone for ophthalmology and medical technology, a groundbreaking glaucoma monitoring device has secured crucial funding from the Canadian Institutes of Health Research (CIHR) to advance its commercialization. This innovative device promises to revolutionize how glaucoma—a leading cause of irreversible blindness—is monitored and managed, offering […]

Preservative-Free Glaucoma Drops vs. MIGS: COPHy Insights Glaucoma management continues to evolve, offering patients treatments that improve efficacy and comfort. At the recent Congress on Controversies in Ophthalmology (COPHy), experts debated the benefits of preservative-free glaucoma drops versus minimally invasive glaucoma surgery (MIGS). Both approaches aim to lower intraocular pressure (IOP) while minimizing side effects—but

Top Glaucoma and Retina Trends at ASCRS & ASOA Annual Meetings The ASCRS & ASOA Annual Meetings are among the most anticipated events in ophthalmology, bringing together leading experts to discuss innovations in eye care. This year, the spotlight was on glaucoma and retina treatments, highlighting new technologies, surgical techniques, and pharmaceutical developments shaping the

Evolution of Glaucoma Treatment: Advancements for Patients and Physicians Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. Over the years, glaucoma treatment has evolved dramatically, offering patients and physicians more effective and less invasive options. From ancient remedies to cutting-edge surgical techniques, the journey of glaucoma management

Sight Sciences Announces Q1 2025 Financial Results on May 8 Sight Sciences, Inc., a leading innovator in ophthalmology and optometry, has announced that it will release its Q1 2025 financial results on May 8, 2025. This eagerly anticipated update will provide insights into the company’s performance, growth trajectory, and strategic initiatives in the first quarter

Emerging Therapies Revolutionize Primary Open Angle Glaucoma Treatment Primary Open Angle Glaucoma (POAG) is the most common form of glaucoma, affecting millions worldwide. Characterized by progressive optic nerve damage and vision loss, POAG has long been managed with traditional treatments like eye drops, laser therapy, and surgery. However, recent advancements in medical science are revolutionizing

Open Angle Glaucoma Market Growth Drives New Business Opportunities The global open-angle glaucoma market is experiencing significant growth, driven by increasing prevalence, technological advancements, and rising awareness about early diagnosis and treatment. As the most common form of glaucoma, open-angle glaucoma (OAG) affects millions worldwide, creating a substantial demand for innovative therapies and diagnostic tools.

Revolutionary Glaucoma Drug Targets Pressure and Nerve Damage in $9.7B Market Glaucoma, a leading cause of irreversible blindness worldwide, has long been a challenge for both patients and medical professionals. Traditional treatments have primarily focused on lowering intraocular pressure (IOP), but a groundbreaking new drug is set to revolutionize the market by addressing both pressure

Palatin’s PL9588 Shows Dual-Action Promise for Glaucoma at ARVO 2025 Exciting advancements in glaucoma treatment were unveiled at the Association for Research in Vision and Ophthalmology (ARVO) 2025 conference, where Palatin Technologies presented promising data on their investigational drug, PL9588. This novel therapy demonstrates a dual-action mechanism targeting both intraocular pressure (IOP) reduction and neuroprotection—a